Novartis’ Additional Indication Of Afinitor For Tuberous Sclerosis Treatment Approved
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharmaceuticals gained approval for anti-cancer Afinitor (everolimus) in the treatment of incurable tuberous sclerosis in Japan, the company announced Nov. 21.